Effects of obinutuzumab administration on cytokine release patterns, ALC, and circulating NK cells. (A) Cytokine release observed pre-, mid-, end-, and postadministration of obinutuzumab observed in n = 38 CLL patients. (B) Changes in circulating CD19⁺ B cells (y-axis left) and CD16⁺56⁺ NK cells (y-axis right) pre-, end-, and postadministration of obinutuzumab observed in n = 38 CLL patients.